VectorBuilder Enables FDA IND Approval of First Umbilical Cord Blood-Derived CAR-T
January 30, 2025
VectorBuilder‘s partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and